Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

Recent & Breaking News (TSXV:BTI.H)

Bioasis Announces Stock Option Grants

Business Wire August 31, 2018

Aeromics, Inc. Appoints Pharmaceutical and Biotech Veterans Mark Day, Ph.D. and Thomas Zindrick, J.D. to Its Board of Directors

Business Wire August 16, 2018

Bioasis Announces Closing of Previously Disclosed Private Placement

Business Wire August 13, 2018

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018

Business Wire July 30, 2018

Bioasis Welcomes John E. Curran & David M. Wurzer to the Company’s Board of Directors

Business Wire July 27, 2018

Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 ™-001 Increased Brain Activity

Business Wire July 25, 2018

Bioasis Announces Non-Brokered Private Placement

Business Wire July 16, 2018

Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic

Business Wire July 11, 2018

Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

Business Wire June 26, 2018

Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor

Business Wire June 12, 2018

Bioasis Announces Publication of Independent Validation of the Company’s xB3 ™ Platform Technology

Business Wire May 30, 2018

Uptick Newswire’s “Stock Day” Podcast Welcomes Dr. Mark Day of Bioasis Technologies Inc.

GlobeNewswire May 29, 2018

Bioasis Announces Closing of Second Tranche of Previously Disclosed Private Placement

Business Wire May 24, 2018

Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer

Business Wire May 21, 2018

Bioasis Announces Closing of First Tranche of Previously Disclosed Private Placement

Business Wire May 17, 2018

Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing

Business Wire May 14, 2018

Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline Hill, Ph.D., Leading Research & Development Operations

Business Wire March 26, 2018

Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors

Business Wire March 21, 2018

Bioasis to Present at the 20th Annual BIO CEO & Investor Conference

Business Wire February 6, 2018

Bioasis Announces Filing of Quarterly Financial Statements and MD&A

Business Wire January 30, 2018